What's happening
This bill creates a state fund to provide grants for improving patient access to and education about clinical trials, including covering ancillary costs.
Why it matters
Addresses financial barriers. By covering “ancillary costs” like travel, lodging, and support for companions, the bill removes major practical obstacles that often prevent lower-income and rural patients from participating in clinical trials, increasing equity in access to cutting-edge treatments.
Broader eligibility and outreach. The fund is open to a wide range of applicants—including hospitals, nonprofits, health departments, and municipalities—enabling diverse organizations to tailor outreach and navigation services for patients with life-threatening or disabling conditions, potentially reaching populations that are underrepresented in clinical research.
Safeguards for ethical participation. The bill requires that any reimbursement programs be approved by institutional review boards and explicitly states that financial support for ancillary costs is not considered coercion or undue inducement, addressing concerns about patient exploitation and ensuring ethical standards are met.
Accountability and measurable impact. Grantees must submit annual reports detailing how funds are spent and what efforts have been made to increase clinical trial access. This ensures transparency, ongoing evaluation, and the ability to refine the program based on real-world outcomes.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Help Patients Join Trials
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Print number 1169a
- Amend and recommit to finance
- Reported and committed to finance
- Referred to health
- Reported and committed to finance
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Help Patients Join Trials
In Assembly Committee · Ways And Means · Sponsor Richard Gottfried
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
1169--A
2021-2022 Regular Sessions
IN SENATE
January 7, 2021
Introduced by Sens. RIVERA, SEPULVEDA -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -- reported favorably from said committee and committed to the Committee on Finance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the public health law, in relation to establishing the clinical trial access and education fund
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The public health law is amended by adding a new section 2424 to read as follows:
§ 2424. Clinical trial access and education fund. 1. Definitions. For the purposes of this section, the following terms shall have the following meanings:
a. "Eligible applicant" means (i) a medical school that sponsors a clinical trial, (ii) a not-for-profit organization with experience and expertise working with patients with life-threatening or disabling conditions or diseases, (iii) a health care provider organization, association or society, (iv) a general hospital defined in article twentyeight of this chapter, (v) a county or city health department, or (vi) a municipality.
b. "Clinical trial" shall have the same meaning as in subdivision two-b of section forty-nine hundred of this chapter.
c. "Ancillary costs" means costs associated with participation in a clinical trial, including but not limited to costs for:
(i) travel;
(ii) lodging;
(iii) parking and tolls;
(iv) a travel companion to assist patients who are elderly, very young, or too ill to travel alone; and
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00038-03-2
(v) other costs considered appropriate jointly by the department, the service providing organization and the trial site.
2. Establishment of fund. There is hereby established within the department a clinical trial access and education fund. Subject to appropriations, the department shall provide grants to eligible applicants on a competitive request for proposal basis to provide one or more of the following services to patients with life-threatening or disabling conditions or diseases, as such terms are defined in section forty-nine hundred of this chapter, to facilitate access to or education on clinical trials of treatments for the patient's condition or disease:
a. transportation services and lodging to provide patients with access to clinical trials or other related treatments while enrolled in a clinical trial or to access testing and other services to determine patient eligibility for a clinical trial;
b. patient outreach and education services to educate patients, their families and health care providers about the existence of and how patients may enroll in clinical trials, under section two hundred seven of this chapter; and
c. patient navigation services to help patients to determine if they are eligible for clinical trials, to help patients to enroll in clinical trials and to assist patients in dealing with insurance or other issues which serve as barriers to patient enrollment in clinical trials.
3. Applications. a. The commissioner shall establish an application process by which eligible applicants may apply for a grant under this section. The application shall include:
(i) the geographic area in which the services shall be provided;
(ii) a detailed description of the services to be provided;
(iii) applicant's experience working with patients with life-threatening or disabling conditions or diseases;
(iv) applicant's ability to provide patient outreach or clinical trial education and navigation services, or coordinate or provide transportation and lodging for patients; and
(v) any other information that the commissioner deems relevant and appropriate.
b. Eligible applicants shall:
(i) have experience and expertise working with patients with lifethreatening or disabling conditions or diseases;
(ii) provide patient outreach, education and health care navigation services;
(iii) collaborate with physicians, health care providers, and clinical trial sponsors to notify a prospective subject about the program when:
(1) the prospective subject consents to a clinical trial; and
(2) funding is available to provide the program for the clinical trial in which the prospective subject participates; and
(iv) reimburse subjects based on financial need to subjects whose income is at or below seven hundred percent of the federal poverty level, which shall include reimbursement for reasonable ancillary costs.
4. Institutional review board requirements. A reimbursement program under this section shall:
a. be approved by the institutional review board associated with the clinical trial; and
b. comply with applicable federal and state laws.
5. Reimbursement. Reimbursement to a subject of ancillary costs under the program:
a. does not constitute an undue inducement to participate in a clinical trial;
b. is not considered coercion or the exertion of undue influence to participate in a clinical trial; and
c. is meant to accomplish parity in access to clinical trials and remove barriers to participation in clinical trials for financially burdened subjects.
6. Reports. Grantees shall file an annual report with the commissioner, in such form and with such information and data as the commissioner prescribes detailing the expenditure of grant funds and summarizing the efforts undertaken to increase patient access to clinical trials.
7. Regulations. The commissioner shall make regulations reasonably necessary to implement the provisions of this section.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to establishing the clinical trial access and education fund
Purpose
This bill creates the Clinical Trial Access and Education Fund, a state grant program within the department to provide funding to address the major barriers to participation in clinical trials in New York State.
Summary of specific provisions
Section 1 amends article 24 of the public health law by adding a new section 2424, the Clinical Trial Access and Education Fund. Subdivision 1 of the new section provides definitions of (a) eligible applicant, (b) clinical trial, and (c) ancillary costs.
Read the full memo (790 words)
Subdivision 2 establishes the clinical trial access and education fund within the department to provide grants to eligible applicants on a competitive request for proposal basis to provide certain services to patients with life-threatening or disabling conditions or diseases. Such services would include: transportation and lodging to patients so they may access a clinical trial or related treatment; patient outreach and education on the existence of and how to enroll in clinical trials; and patient navigation services to help patients determine eligibility for clinical trials.
Subdivision 3 establishes an application process for eligible appli- cants. Applications shall include: the geographic area in which services will be provided, a description of the services provided, the appli- cant's experience in working with patients who have life-threatening Or disabling conditions or diseases, the applicant's ability to provide patient outreach or clinical trial education and navigation services or coordinate transportation or lodging for patients, and any other infor- mation deemed appropriate. Provides for the eligibility of applicants to include experience working with patients with life-threatening or disa- bling conditions, the ability to collaborate with physicians, health care providers, and trial sponsors to notify a subject about the program when appropriate, among other criteria.
Subdivision 4 provides for institutional review board requirements. A reimbursement program under this section shall be approved by the insti- tutional review board associated with the trial and comply with applica- ble federal and state laws.
Subdivision 5 provides that reimbursement of ancillary costs under the program shall not constitute inducement to participate in the trial, or be considered coercion or exertion of undue influence to participate, and is meant to accomplish parity in trials and remove barriers of participation.
Subdivision 6 provides for reporting requirements. Grantees must file reports annually with the commissioner detailing the expenditure of grant funds, and the efforts taken to increase patient access to clin- ical trials. Subdivision 7 provides that the commissioner shall develop regulations necessary to implement this section.
Section 2 establishes the effective date, which is immediately.
Justification
New therapies to treat cancer and other life threatening diseases are being developed at an increasing pace. Clinical trials are the most effective, scientifically valid method of determining the benefits of experimental treatments. They are critical to improving health care and mortality rates for patients with cancer and other life-threatening diseases.
A large number of pediatric enrollees in clinical trials led to the discovery of groundbreaking therapies and a survival rate of over 80% for childhood cancer. To achieve a similar rate of success for adults with cancer and other diseases, information and access to clinical trials must be made more widely available to patients and their treating health care providers.
A number of studies have looked at the reasons for low adult patient participation in clinical trials. One such study conducted by the University of California Davis' Cancer Center surveyed patients and physicians about clinical trial participation. Of the 276 patients surveyed, only 76 said they would participate in clinical trials if recommended by their physician. Of this, only 39 actually enrolled.
The two most common reasons why patients declined to participate had to do with a desire for other treatments and the distance to the cancer center. The study authors made a series of recommendations to overcome these barriers including the need for greater physician and patient education on the status, availability and benefits of clinical trials as well as the need to address geographical issues that serve as strong deterrents to clinical trial access.
The Clinical Trial Access and Education Fund will address these major barriers identified by the clinical research and anecdotally from patients and providers in New York, it will provide grants to non-for- profit community groups, health care provider associations, and research centers that conduct clinical trials so they may provide and/ or facili- tate patient navigation, transportation, lodging and patient and provid- er education to achieve greater patient participation in clinical trials.
Prior legislative history
2013-2014: S6442
2015-2016: 8777
2017-2018: 51216
2019-2020: S932/A1035 Gottfried
Fiscal implications
None - subject to available appropriations.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.